Nautilus Biotechnology, Inc. NAUT
2.19 USD -0.16 (-6.79%)
Nov 4, 2026, 11:33 AM EST
2.15 Day range 2.39
0.841 52-week range 4.31
- YTD
- +12.33%
- 1 year
- +37.76%
Analyst view
Consensus: buy
Buy
Price target (mean) 3.44 +56.9% upside
Now 2.19
- Target (low)
- 1.75
- Target (mean)
- 3.44
- Target (high)
- 5.00
Ratings (0m) 5 2 buy · 2 hold · 1 sell
- Strong buy0
- Buy2
- Hold2
- Sell0
- Strong sell1
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.16333 | -0.18 – -0.15 | -0.14 | -16.7% | 0 | 0.0% | 3 |
| Next quarter | -0.18 | -0.20 – -0.15 | -0.15 | -20.0% | 0 | 0.0% | 3 |
| Current year | -0.58333 | -0.60 – -0.57 | -0.51 | -14.4% | 0 | 0.0% | 3 |
| Next year | -0.74333 | -0.84 – -0.66 | -0.58333 | -27.4% | 3.62M | 0.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Goldman Sachs | Downgrade | Neutral | Sell |
| Jun 27, 2024 | Guggenheim | Initiated | — | Buy |
| Aug 3, 2023 | Morgan Stanley | Reiterated | Equal-Weight | Equal-Weight |
| Aug 3, 2022 | Morgan Stanley | Maintained | — | Equal-Weight |
| Aug 3, 2022 | Goldman Sachs | Maintained | — | Neutral |
| Jul 14, 2022 | Goldman Sachs | Maintained | — | Neutral |
| Apr 13, 2022 | Goldman Sachs | Maintained | — | Neutral |
| Jan 6, 2022 | Morgan Stanley | Initiated | — | Equal-Weight |
| Nov 2, 2021 | Cowen & Co. | Initiated | — | Outperform |
| Aug 4, 2021 | Goldman Sachs | Initiated | — | Neutral |
| Jul 13, 2021 | Jefferies | Initiated | — | Buy |